18
December
Major breakthrough in liver cancer treatment! Professor Xia Limin/Professor Huang Wenjie's joint team at Tongji Hospital provides a new strategy for liver cancer immunotherapy
In March 2023, Professor Xia Limin from the Department of Gastroenterology of Tongji Hospital and Professor Huang Wenjie from the Department of hepatology were published in the top Journal of hepatology (2021 IF: 30.083) published the title "FGF19/FGFR4-mediated elevation of ETV4 facilitates hepatocellular carcinoma metastasis by upregulating PD-L1. and CCL2 "research paper. This study revealed the molecular mechanism of liver cancer metastasis, verified the anti-tumor effect of multi-drug combination through animal models, and is expected to be translated into clinical practice and bring good news to patients with liver cancer.
Liver cancer is a serious threat to the life and health of Chinese people. It is the fourth common malignant tumor and the second cause of death from cancer in China. Due to the insidious onset of liver cancer, most patients have been diagnosed at an advanced stage and have lost the opportunity for radical surgical treatment. Antitumor drug therapy is the first choice for patients with advanced liver cancer. Unfortunately, the drugs used for the first-line treatment of liver cancer are very limited and the effect is not optimistic.Therefore, it is urgent to explore new therapeutic strategies for different subtypes of liver cancer. Xia Limin/Huang Wenjie's team found that PD-L1 inhibitors combined with FGFR4 inhibitor BLU554 or MAPK inhibitor trametinib can effectively inhibit ETV4-mediated liver cancer metastasis. This study provides a novel combination immunotherapy strategy for liver cancer patients with high ETV4 expression.
Professor Limin Xia and Professor Wenjie Huang of Tongji Hospital are co-corresponding authors of the article, and members of the research team Meng Xie, Zhuoying Lin, Xiaoyu Ji, Xiangyuan Luo and Zerui Zhang are co-first authors of the article.
